Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The Effectiveness and Safety of Apixaban Versus Warfarin in Non-valvular Atrial Fibrillation (NVAF) Patients With the History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study

Next Previous
Trial Profile

The Effectiveness and Safety of Apixaban Versus Warfarin in Non-valvular Atrial Fibrillation (NVAF) Patients With the History of Osteoporosis and/or Fracture: A Nation-wide Population Based Study

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Warfarin
  • Indications Embolism; Haemorrhagic stroke; Ischaemic stroke
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 28 May 2020 Planned End Date changed from 31 May 2020 to 31 Mar 2020.
  • 28 May 2020 Planned primary completion date changed from 31 May 2020 to 31 Mar 2020.
  • 28 May 2020 Planned initiation date changed from 31 Mar 2020 to 18 Nov 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top